-
Basel, December 2, 2021 — Novartis today holds an investor event to provide a comprehensive overview of the company’s progress in advancing its industry-leading R&D engine.InnovationFuture of HealthcareDrug Development
-
Novartis is collaborating with Microsoft to apply machine learning to medicinal chemistry — part of an effort to leverage AI to bring treatments to patients more efficiently.
Biomedical ResearchData ScienceDrug DevelopmentDrug DiscoveryEmerging Technology -
John Tsai, Head of Global Drug Development and Chief Medical Officer, describes how he balances innovation and patient needs.
Drug DevelopmentInnovationWorking at Novartis -
Basel, September 23, 2020 – Novartis Gene Therapies recently received feedback from the US Food and Drug Administration (FDA) following their review of data from the STRONG study of the intrathecal (IT) formulation of AVXS-101 in older patients with spinal muscular atrophy (SMA). The FDA has acknowledged the potential of AVXS-101 IT in this…Drug DevelopmentClinical TrialsAd Hoc
-
Basel, October 9, 2020 — Novartis today announced that the European Medicines Agency (EMA) has granted PRIME designation for iptacopan (LNP023) in C3 glomerulopathy (C3G). PRIME is a program launched by the EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary program is based on enhanced…Reimagine MedicineDrug Development
-
Bâle, le 26 janvier 2021 - En commentant les résultats, Vas Narasimhan, CEO de Novartis, a déclaré: «En dépit des défis posés par le Covid-19, Novartis a réalisé une excellente performance en 2020 dans toutes ses priorités stratégiques. Sur le plan opérationnel, nous avons augmenté notre chiffre d’affaires et continué d’améliorer nos marges…Reimagine MedicineFuture of HealthcareDrug DevelopmentAd HocAccess to Healthcare
-
Basel, 26. Januar 2021 — Die Ergebnisse 2020 kommentierte Vas Narasimhan, CEO von Novartis: «Novartis hat 2020 trotz der Herausforderungen durch COVID-19 bei allen strategischen Prioritäten solide Ergebnisse erzielt. Operativ konnten wir den Umsatz steigern und die operativen Kerngewinnmargen bei Innovative Medicines verbessern. Wir haben unsere…Reimagine MedicineFuture of HealthcareDrug DevelopmentAd HocAccess to Healthcare
-
Basel, January 26, 2021 - commenting on 2020 results, Vas Narasimhan, CEO of Novartis, said: “Novartis delivered a solid performance in 2020 across our strategic priorities, despite the challenges of COVID-19. Operationally, we grew sales and continued to improve core operating margins for Innovative Medicines. We advanced our next wave of…Reimagine MedicineFuture of HealthcareDrug DevelopmentAd HocAccess to Healthcare
-
Basel, May 27, 2021 — Novartis and Molecular Partners announced today the start of the clinical trial EMPATHY, a Phase 2 and 3 study, to explore the use of its novel DARPin® therapeutic candidate ensovibep (MP0420) for the treatment of COVID-19. Novartis will conduct the clinical trial program for ensovibep, with Molecular Partners as sponsor of…Reimagine MedicineDrug DevelopmentClinical Trials
-
Basel, December 13, 2019 — Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Beovu® (brolucizumab 6 mg), also known as RTH258, an investigational product for the treatment of wet age-related macular degeneration (AMD).InnovationDrug Development
-
Basel, June 2, 2020 — Novartis today announced that it has received notice from the US Food and Drug Administration (FDA) that the agency has extended its review of the Supplemental Biologics License Application (sBLA) for ofatumumab (OMB 157), a self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis. Regulatory…NeuroscienceDrug Development
-
Novartis researchers aim to improve the lives of patients with osteoarthritis.
Drug DiscoveryMusculoskeletal DiseasesScientific ResearchDrug Development
-
Novartis is collaborating with Microsoft to apply machine learning to medicinal chemistry — part of an effort to leverage AI to bring treatments to patients more efficiently.
-
John Tsai, Head of Global Drug Development and Chief Medical Officer, describes how he balances innovation and patient needs.
-
Novartis researchers aim to improve the lives of patients with osteoarthritis.